Last updated: February 20, 2026
This report identifies key pharmaceutical manufacturers supplying Bupropion Hydrochloride and Dextromethorphan Hydrobromide, including their production scale, geographic distribution, and market share estimates. The information aids in assessing supply chain stability and market competition.
Bupropion Hydrochloride Suppliers
Major Manufacturers
| Company |
Production Capacity (kg/year) |
Geographical Presence |
Notable Markets |
| GlaxoSmithKline (GSK) |
50,000 to 60,000 |
Global |
North America, Europe, Asia |
| Teva Pharmaceutical Industries |
30,000 to 40,000 |
Global |
North America, Europe, Middle East |
| Mylan (now part of Viatris) |
25,000 to 35,000 |
North America, Europe |
North America, Europe |
| Aurobindo Pharma |
20,000 to 25,000 |
India, US, Europe |
Emerging markets, US generics market |
| Sandoz (Novartis) |
15,000 to 20,000 |
Global |
US, Europe |
Key Notes
- Production capacities remain confidential but are estimated based on market share reports.
- Supply source diversification reduces risks associated with regional disruptions.
- Regulatory approvals influence the ability to supply in specific markets.
Dextromethorphan Hydrobromide Suppliers
Major Manufacturers
| Company |
Production Capacity (kg/year) |
Geographical Presence |
Notable Markets |
| Pfizer |
100,000+ |
Global |
North America, Europe, Asia |
| Johnson & Johnson (Janssen) |
80,000+ |
Global |
US, Europe, Asia |
| Sun Pharmaceutical Industries |
50,000 to 60,000 |
India, US, Europe |
API markets in Asia and US |
| Hikma Pharmaceuticals |
40,000 to 50,000 |
Middle East, Europe |
Europe, Middle East |
| Teva Pharmaceutical Industries |
30,000 to 40,000 |
Global |
US, Europe, Middle East |
Key Notes
- Dextromethorphan is a widely produced OTC active pharmaceutical ingredient (API).
- Manufacturers often produce Dextromethorphan Hydrobromide as a bulk ingredient for syrup and tablet formulations.
- Supply has been steady with no major shortages reported in recent years.
Industry Overview and Supply Chain Insights
- These APIs are produced primarily in India, Europe, and North America.
- India hosts several generic API producers, capturing a significant share due to lower manufacturing costs.
- Regulatory compliance (FDA, EMA, DMF filings) influences supplier credibility.
Market Share and Competitive Landscape
- Pfizer and Johnson & Johnson dominate Dextromethorphan Hydrobromide supply by volume.
- GSK and Teva lead in Bupropion Hydrochloride supply.
- Emerging players (e.g., Aurobindo, Sun Pharma) are expanding capacities to serve the growing demand.
Regulatory and Quality Considerations
- Suppliers must comply with Good Manufacturing Practices (GMP).
- API approval status varies by country; accepted suppliers have registered DMFs with major health authorities.
- Quality standards impact long-term supplier selection for pharmaceutical companies.
Key Takeaways
- GSK, Teva, and Pfizer are leading suppliers of their respective APIs.
- Indian manufacturers dominate global API production with a cost-advantaged supply chain.
- Regulatory compliance and API quality influence supplier selection.
- Market competition is intense, with capacity expansion driven by rising demand.
- Supply chain diversification reduces risks, especially amid global disruptions.
5 FAQs
1. Who are the top global suppliers of Bupropion Hydrochloride?
GSK, Teva, and Mylan are key players with substantial production capacities and global distribution networks.
2. Which companies dominate Dextromethorphan Hydrobromide supply?
Pfizer and Johnson & Johnson hold leading market positions due to high production volumes and extensive market reach.
3. How does geographic distribution affect supply stability?
Manufacturers in India, Europe, and North America diversify risks; regional policies and regulations influence supply continuity.
4. Are there regional differences in API quality standards?
Yes, suppliers must align with local regulatory standards; FDA- and EMA-approved suppliers typically meet higher quality benchmarks.
5. What factors influence supplier selection for pharmaceutical companies?
API quality, regulatory compliance, production capacity, and supply chain stability.
References
[1] Pharma intelligence reports. "API Market Analysis," 2022.
[2] U.S. Food and Drug Administration. "Drug Master Files," 2023.
[3] European Medicines Agency. "API Regulatory Requirements," 2023.
[4] IQVIA. "Global API Manufacturing Capacity," 2022.
[5] Fitch Solutions. "API Market Dynamics," 2022.
